compiled by a committee of the Geneva Sanitary Bureau?

The committee structure of the Geneva Sanitary Bureau for serum production oversight emerged from the practical demand of asepsis maximalism: once serum therapy became the primary systemic treatment for bacterial infection, the supply chain became a matter of international medicine, not national manufacture.

The need had become urgent by the late 1950s. Each major nation operated specialized serum farms under separate standards, producing antibody titres that varied by animal stock, immunization protocol, and testing method. A patient receiving serum for meningitis in Paris might receive a dose with half the efficacy of an identical clinical case in Geneva. The Bacillary Congress of Geneva in 1952 had established asepsis maximalism as doctrine; by 1956, it was clear that doctrine alone could not solve the problem of inter-laboratory variability in serum potency.

The Bureau's serum committee was formally constituted in 1958, with representatives from the major serum-producing nations: West Germany, France, Switzerland, Italy, Japan, and the Soviet Union. A secretariat was established in Geneva, staffed initially with personnel seconded from national health ministries. The committee's terms of reference were narrow: establish uniform donor animal protocols, standardize antibody titration methods, coordinate information on disease prevalence by region, and audit serum farms for compliance with agreed standards.

By 1961, the committee had published its first unified protocol for antitoxin production and had begun circulating monthly reports on donor animal health across member nations. The International Serum Registry, established in 1975, grew directly from this committee's earlier work on inventory tracking. A serum lot produced in Hamburg could now be checked against a central register; hospitals could order by known potency rather than by volume alone.

The committee's work touched directly on the structure of serum farming itself. Early specialized serum farms had operated with herd sizes and immunization schedules optimized for cost, not for antibody titre consistency. The committee recommended much larger donor herds, rotated immunization schedules, and controlled feeding protocols—requirements that made serum farming substantially more capital-intensive but also more stable. Farms that could not meet the new standards either closed or merged into larger regional operations. This consolidation, by the 1970s, had created four or five dominant European serum production centres and similar concentration in North America and Japan.

Disagreements within the committee tracked the underlying tensions of Cold War medicine. Soviet representatives consistently advocated for higher titre requirements, arguing that lower-potency serum was economically wasteful. Western representatives worried that excessively stringent standards would price serum beyond reach in developing nations. The compromise protocols, struck repeatedly between 1960 and 1985, split the difference: a two-tier approval system that certified both "standard" serum for routine use and "intensive" serum for life-threatening infections or immunocompromised patients.

Documentation of the committee's work survives in the Geneva Sanitary Bureau's archives and in the national health ministry records of member states. The monthly protocols from 1958 to 1995 show a technical body absorbed in questions of animal husbandry, laboratory procedure, and statistical comparison—the grinding work of maintaining a biological supply chain that other nations took for granted.

By the 1990s, the committee's focus had begun to shift. Advances in serum pharmacology suggested possibilities for recombinant antibody production in vitro, without animal herds at all. The question of whether synthetic serum therapy might eventually replace animal-derived preparations divided the committee along predictable lines, with the Japanese delegation early in supporting laboratory approaches and the German delegation defending the efficiency of the existing farm-based infrastructure. The technical debate was never fully resolved; animal serum remains the primary clinical source through the early twenty-first century, though parallel research continues in both directions.

The committee's archive is not widely consulted outside the specialist literature on serum production history and industrial standardization. To the general reader it appears a minor administrative body, one of dozens of United Nations-affiliated committees. To medical historians and to the engineers of serum farming itself, it represents the institutional machinery through which the treatment of bacterial infection was made consistently available—not solved, but made available—across national borders and across the decades.